bicifadine serotoninnorepinephrinedopamine reuptake inhibitor sndri discovered american cyanamid analgesic drug candidate licensed dov pharmaceutical american cyanamid acquired january dov licensed rights bicifadine xtl biopharmaceuticals bicifadine failed phase iii clinical trial chronic lower back xtl ran phaseiib clinical trial pain caused diabetic neuropathy failed xtl terminated agreement dov acquired euthymics bioscience intended continue development candidates dovs bicifadine nonopioid nonnsaid mechanism treatment pain less abuse potential opioid drugs less propensity cause gastric ulcers nsaid drug purported serotonin sert noradrenaline transporter net inhibitor also effects dopamine transporter dat effectively making broadspectrum monoamine transporter inhibitor triple reuptake httpsenwikipediaorgwikibicifadine